Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer

Journal of Clinical Oncology

Volumn 28, Issue 36, 2010, Pages 5294-5300

  Argiris, Athanassios ^a   Heron, Dwight E ^a   Smith, Ryan P ^a   Kim, Seungwon ^a   Gibson, Michael K ^a   Lai, Stephen Y ^a   Branstetter, Barton F ^a   Posluszny, Donna M ^a   Wang, Lin ^a   Seethala, Raja R ^a   Dacic, Sanja ^a   Gooding, William ^a   Grandis, Jennifer R ^a   Johnson, Jonas T ^a   Ferris, Robert L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CIPROFLOXACIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; PROTEIN P16;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEAD AND NECK CANCER; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; INJECTION SITE REACTION; KIDNEY FAILURE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; RATING SCALE; SQUAMOUS CELL CARCINOMA; STOMACH TUBE; SURVIVAL TIME; THROMBOCYTOPENIA; TISSUE MICROARRAY; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WART VIRUS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TAXOIDS; YOUNG ADULT;

EID: 79951861341     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.6423     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Argiris A, Karamouzis MV, Raben D, et al: Head and neck cancer. Lancet 371:1695-1709, 2008 (Pubitemid 351671886)
3. Pignon JP, le Maitre A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
4. Pointreau Y, Garaud P, Chapet S, et al: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498-506, 2009
5. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007 (Pubitemid 350005152)
6. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007 (Pubitemid 350005151)
7. Adelstein DJ, Moon J, Hanna E, et al: Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/ concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). Head Neck 32:221-228, 2010
8. Karamouzis MV, Grandis JR, Argiris A: Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298:70-82, 2007 (Pubitemid 47026772)
9. Lopez-Albaitero A, Ferris RL: Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 133:1277-1281, 2007 (Pubitemid 350294259)
10. Lopez-Albaitero A, Lee SC, Morgan S, et al: Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58:1853-1864, 2009
11. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
12. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. Passero VA, Branstetter BF, Shuai Y, et al: Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol 21:2278-2283, 2010
15. List MA, D'Antonio LL, Cella DF, et al: The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale: A study of utility and validity. Cancer 77:2294-2301, 1996 (Pubitemid 26162422)
16. Singhi AD, Westra WH: Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 116:2166-2173, 2010
17. Dacic S, Shuai Y, Yousem S, et al: Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 23:159-168, 2010
18. Chung CH, Ely K, McGavran L, et al: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170-4176, 2006 (Pubitemid 46622295)
19. Kies MS, Holsinger FC, Lee JJ, et al: Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial. J Clin Oncol 28:8-14, 2010
20. Lefebvre J, Pointreau Y, Rolland F, et al: Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol 27: 303s, 2009 (suppl 15S; abstr 6010)
21. Haddad RI, Tishler RB, Norris C, et al: Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 27:4448-4453, 2009
22. Mesia R, Vázquez S, Grau JJ, et al: A singlearm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN. J Clin Oncol 27:304s, 2009 (suppl 15S; abstr 6015)
23. Wanebo HJ, Ghebremichael M, Burtness B, et al: Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol 25:302s, 2007 (suppl 18S; abstr 6015)
24. McLaughlin BT, Gokhale AS, Shuai Y, et al: Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: The University of Pittsburgh experience. Laryngoscope 120:71-75, 2010
25. Licitra L, Rolland F, Bokemeyer C, et al: Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN. J Clin Oncol 27:302s, 2009 (suppl 15S; abstr 6005)
26. Gillison ML, Harris J, Westra W, et al: Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol 27:301s, 2009 (suppl 15S; abstr 6003)
27. Andrade Filho PA, Lopez-Albaitero A, Gooding W, et al: Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother 33:83-91, 2010